PTC Therapeutics (NASDAQ:PTCT) Director Emma Reeve Sells 734 Shares

PTC Therapeutics, Inc. (NASDAQ:PTCT) Director Emma Reeve sold 734 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $76.00, for a total value of $55,784.00. Following the completion of the sale, the director owned 10,666 shares of the company’s stock, valued at approximately $810,616. This trade represents a 6.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Emma Reeve also recently made the following trade(s):

• On Wednesday, December 3rd, Emma Reeve sold 733 shares of PTC Therapeutics stock. The stock was sold at an average price of $78.62, for a total transaction of $57,628.46.
• On Friday, November 21st, Emma Reeve sold 10,000 shares of PTC Therapeutics stock. The stock was sold at an average price of $79.50, for a total transaction of $795,000.00.
• On Wednesday, November 12th, Emma Reeve sold 7,333 shares of PTC Therapeutics stock. The shares were sold at an average price of $74.50, for a total transaction of $546,308.50.
• On Thursday, October 30th, Emma Reeve sold 15,666 shares of PTC Therapeutics stock. The stock was sold at an average price of $69.50, for a total value of $1,088,787.00.

PTC Therapeutics Stock Performance

Shares of PTCT opened at $76.70 on Wednesday. PTC Therapeutics, Inc. has a 52-week low of $35.95 and a 52-week high of $87.50. The business’s fifty day moving average is $76.06 and its 200-day moving average is $62.32. The firm has a market cap of $6.16 billion, a price-to-earnings ratio of 8.96 and a beta of 0.49.

PTC Therapeutics (NASDAQ:PTCT) last released its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, beating the consensus estimate of ($1.19) by $1.39. PTC Therapeutics had a negative return on equity of 194.11% and a net margin of 42.25%.The business had revenue of $211.01 million for the quarter, compared to analyst estimates of $177.42 million. During the same period last year, the firm posted ($1.39) earnings per share. PTC Therapeutics’s revenue was up 7.2% compared to the same quarter last year. As a group, research analysts forecast that PTC Therapeutics, Inc. will post -4.52 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Citigroup increased their price target on PTC Therapeutics from $50.00 to $75.00 and gave the company a “neutral” rating in a research note on Wednesday, November 5th. Weiss Ratings reissued a “hold (c)” rating on shares of PTC Therapeutics in a research note on Monday, December 29th. Barclays boosted their price target on PTC Therapeutics from $46.00 to $68.00 and gave the stock an “equal weight” rating in a report on Wednesday, November 5th. Cowen reiterated a “hold” rating on shares of PTC Therapeutics in a report on Wednesday, November 5th. Finally, TD Cowen boosted their target price on shares of PTC Therapeutics from $50.00 to $63.00 and gave the stock a “hold” rating in a report on Wednesday, November 5th. Nine analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $76.00.

Institutional Investors Weigh In On PTC Therapeutics

Several large investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC lifted its stake in PTC Therapeutics by 160.0% in the fourth quarter. GAMMA Investing LLC now owns 1,451 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 893 shares during the period. IFP Advisors Inc increased its stake in shares of PTC Therapeutics by 68.1% in the 3rd quarter. IFP Advisors Inc now owns 765 shares of the biopharmaceutical company’s stock valued at $47,000 after acquiring an additional 310 shares in the last quarter. Cambria Investment Management L.P. lifted its position in shares of PTC Therapeutics by 24.9% during the 3rd quarter. Cambria Investment Management L.P. now owns 11,634 shares of the biopharmaceutical company’s stock valued at $714,000 after acquiring an additional 2,322 shares during the period. CIBC Bancorp USA Inc. bought a new position in PTC Therapeutics during the third quarter worth $508,000. Finally, Danske Bank A S bought a new position in PTC Therapeutics during the third quarter worth $1,152,000.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.